Who benefits from diagnostic labels for developmental disorders?

Publication date

2022-08

Authors

Werkhoven, SanderISNI 0000000453679758
Anderson, JoelORCID 0000-0002-4799-2946ISNI 0000000081409203
Robeyns, IngridORCID 0000-0002-2893-1814ISNI 0000000116021525

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by_nc

Abstract

The number of diagnoses of developmental disorders is on the rise and the use of labels for developmental disorders, such as attention-deficit/hyperactivity disorder and autism spectrum disorder, is widening. Diagnostic labels can play an important role in helping those who display atypical behaviour and their caregivers to cope with associated challenges and, possibly, to get treatment. But these labels are increasingly contested and associated with a variety of harmful effects. In this paper, we analyze the role diagnostic labels can play in four different contexts (scientific, therapeutic, social, and administrative) and identify what various stakeholders stand to gain or lose with continued, expanded, or abolished use of those labels. Our analysis reveals labels serve different purposes in each of these contexts, benefitting different stakeholders. Any overall evaluation, critique, or defence of labels needs to consider the interests of all stakeholders in these contexts

Keywords

Classification, Illness, Clinical Neurology, Developmental Neuroscience, Pediatrics, Perinatology, and Child Health

Citation

Werkhoven, S, Anderson, J & Robeyns, I 2022, 'Who benefits from diagnostic labels for developmental disorders?', Developmental Medicine and Child Neurology, vol. 64, no. 8, pp. 944-949. https://doi.org/10.1111/dmcn.15177